{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:13:38Z","timestamp":1792725218379,"version":"4.5.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 AI169296"],"award-info":[{"award-number":["RO1 AI169296"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R61HL161818"],"award-info":[{"award-number":["R61HL161818"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40259-025-00756-8","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:44:48Z","timestamp":1768031088000},"page":"215-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity of Gene and Cell Therapies"],"prefix":"10.1007","volume":"40","author":[{"given":"Kirk","family":"Hofman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Jangied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0569-2865","authenticated-orcid":false,"given":"Sathy V.","family":"Balu-Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"3","key":"756_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1189\/jlb.69.3.474","volume":"69","author":"TH Flo","year":"2001","unstructured":"Flo TH, Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol. 2001;69(3):474\u201381.","journal-title":"J Leukoc Biol"},{"key":"756_CR2","first-page":"11","volume":"64","author":"E Brzezinska-Blaszczyk","year":"2010","unstructured":"Brzezinska-Blaszczyk E, Wierzbicki M. [Mast cell Toll-like receptors (TLRs)]. Postepy Hig Med Dosw. 2010;64:11\u201321.","journal-title":"Postepy Hig Med Dosw"},{"issue":"4","key":"756_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2567.2005.02122.x","volume":"114","author":"G Kollisch","year":"2005","unstructured":"Kollisch G, Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology. 2005;114(4):531\u201341.","journal-title":"Immunology"},{"issue":"1","key":"756_CR4","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1038\/mi.2008.47","volume":"1","author":"E Cario","year":"2008","unstructured":"Cario E. Barrier-protective function of intestinal epithelial Toll-like receptor 2. Mucosal Immunol. 2008;1(1):S62\u20136.","journal-title":"Mucosal Immunol"},{"issue":"2","key":"756_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00232-009-9175-3","volume":"229","author":"T Melkamu","year":"2009","unstructured":"Melkamu T, Regulation of TLR2 expression and function in human airway epithelial cells. J Membr Biol. 2009;229(2):101\u201313. https:\/\/doi.org\/10.1007\/s00232-009-9175-3.","journal-title":"J Membr Biol"},{"issue":"11","key":"756_CR6","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/1521-4141(200111)31:11<3388::AID-IMMU3388>3.0.CO;2-Q","volume":"31","author":"D Jarrossay","year":"2001","unstructured":"Jarrossay D, Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol. 2001;31(11):3388\u201393.","journal-title":"Eur J Immunol"},{"issue":"4","key":"756_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1365-2567.2012.03587.x","volume":"136","author":"EP Browne","year":"2012","unstructured":"Browne EP. Regulation of B-cell responses by Toll-like receptors. Immunology. 2012;136(4):370\u20139.","journal-title":"Immunology"},{"issue":"7","key":"756_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nri1391","volume":"4","author":"S Akira","year":"2004","unstructured":"Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499\u2013511.","journal-title":"Nat Rev Immunol"},{"issue":"27","key":"756_CR9","doi-asserted-by":"publisher","first-page":"6464","DOI":"10.1016\/j.biomaterials.2013.05.016","volume":"34","author":"HC Chen","year":"2013","unstructured":"Chen HC, Selectively targeting the toll-like receptor 9 (TLR9)\u2013IRF 7 signaling pathway by polymer blend particles. Biomaterials. 2013;34(27):6464\u201372.","journal-title":"Biomaterials"},{"key":"756_CR10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143780","author":"M Muhuri","year":"2021","unstructured":"Muhuri M, Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Investig. 2021. https:\/\/doi.org\/10.1172\/JCI143780.","journal-title":"J Clin Investig"},{"issue":"8","key":"756_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/90609","volume":"2","author":"S Akira","year":"2001","unstructured":"Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675\u201380.","journal-title":"Nat Immunol"},{"issue":"7","key":"756_CR12","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1172\/JCI68205","volume":"123","author":"SM Faust","year":"2013","unstructured":"Faust SM, CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Investig. 2013;123(7):2994\u20133001.","journal-title":"J Clin Investig"},{"issue":"9","key":"756_CR13","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1128\/JVI.02524-12","volume":"87","author":"B Venkatakrishnan","year":"2013","unstructured":"Venkatakrishnan B, Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol. 2013;87(9):4974\u201384.","journal-title":"J Virol"},{"key":"756_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3389\/fimmu.2019.01586","volume":"10","author":"M Brisse","year":"2019","unstructured":"Brisse M, Ly H. Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5. Front Immunol. 2019;10:1586.","journal-title":"Front Immunol"},{"key":"756_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120474","author":"W Shao","year":"2018","unstructured":"Shao W, Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.120474.","journal-title":"JCI Insight"},{"issue":"3","key":"756_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/hgtb.2019.013","volume":"30","author":"JSS Butterfield","year":"2019","unstructured":"Butterfield JSS, Biswas M, Shirley JL, Kumar SRP, Sherman A, Terhorst C, et al. TLR9-activating CpG-B ODN but not TLR7 agonists triggers antibody formation to factor IX in muscle gene transfer. Hum Gene Ther Methods. 2019;30(3):81\u201392. https:\/\/doi.org\/10.1089\/hgtb.2019.013.","journal-title":"Hum Gene Ther Methods"},{"issue":"24","key":"756_CR17","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1182\/blood-2016-11-751040","volume":"129","author":"GL Rogers","year":"2017","unstructured":"Rogers GL, Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8(+) T cells. Blood. 2017;129(24):3184\u201395.","journal-title":"Blood"},{"issue":"3","key":"756_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ymthe.2019.11.011","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, Keeler GD, Sherman A, Zolotukhin I, Markusic DM, Hoffman BE, et al. Type I IFN sensing by cDCs and CD4(+) T cell help are both requisite for cross-priming of AAV capsid-specific CD8(+) T cells. Mol Ther. 2020;28(3):758\u201370. https:\/\/doi.org\/10.1016\/j.ymthe.2019.11.011.","journal-title":"Mol Ther"},{"issue":"3","key":"756_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00281-004-0180-4","volume":"26","author":"T Ito","year":"2005","unstructured":"Ito T, Wang YH, Liu YJ. Plasmacytoid dendritic cell precursors\/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Springer Semin Immunopathol. 2005;26(3):221\u20139.","journal-title":"Springer Semin Immunopathol"},{"issue":"26","key":"756_CR20","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan S, AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519\u201330.","journal-title":"N Engl J Med"},{"issue":"10","key":"756_CR21","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1111\/j.1600-6143.2006.01476.x","volume":"6","author":"PP Boor","year":"2006","unstructured":"Boor PP, Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transplant. 2006;6(10):2332\u201341.","journal-title":"Am J Transplant"},{"issue":"4","key":"756_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419\u201322.","journal-title":"Nat Med"},{"issue":"5","key":"756_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","volume":"16","author":"S Sivori","year":"2019","unstructured":"Sivori S, Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16(5):430\u201341.","journal-title":"Cell Mol Immunol"},{"key":"756_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","volume":"6","author":"W Wang","year":"2015","unstructured":"Wang W, NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.","journal-title":"Front Immunol"},{"issue":"12","key":"756_CR25","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1172\/JCI122372","volume":"128","author":"K Kuranda","year":"2018","unstructured":"Kuranda K, Jean-Alphonse P, Leborgne C, Hardet R, Collaud F, Marmier S, et al. Exposure to wild-type AAV drives distinct capsid immunity profiles in humans. J Clin Investig. 2018;128(12):5267\u201379. https:\/\/doi.org\/10.1172\/JCI122372.","journal-title":"J Clin Investig"},{"key":"756_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173510","author":"SM Salabarria","year":"2024","unstructured":"Salabarria SM, Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Investig. 2024. https:\/\/doi.org\/10.1172\/JCI173510.","journal-title":"J Clin Investig"},{"issue":"13-14","key":"756_CR27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/hum.2023.194","volume":"35","author":"E Kropf","year":"2024","unstructured":"Kropf E,  Complement system response to adeno-associated virus vector gene therapy. Hum Gene Ther. 2024;35(13\u201314):425\u201338. https:\/\/doi.org\/10.1089\/hum.2023.194.","journal-title":"Hum Gene Ther"},{"issue":"11-12","key":"756_CR28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1089\/hum.2023.018","volume":"34","author":"C West","year":"2023","unstructured":"West C,  Complement activation by adeno-associated virus-neutralizing antibody complexes. Hum Gene Ther. 2023;34(11\u201312):554\u201366. https:\/\/doi.org\/10.1089\/hum.2023.018.","journal-title":"Hum Gene Ther"},{"issue":"13","key":"756_CR29","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek A, Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N Engl J Med. 2023;389(13):1203\u201310. https:\/\/doi.org\/10.1056\/NEJMoa2307798.","journal-title":"N Engl J Med"},{"issue":"3","key":"756_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/JND-221639","volume":"10","author":"A Lek","year":"2023","unstructured":"Lek A, Meeting report: 2022 Muscular Dystrophy Association summit on \u201csafety and challenges in gene transfer therapy.\u201d J Neuromuscul Dis. 2023;10(3):327\u201336. https:\/\/doi.org\/10.3233\/JND-221639.","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"756_CR31","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","volume":"55","author":"MD Hoggan","year":"1966","unstructured":"Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci USA. 1966;55(6):1467\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3685","key":"756_CR32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1126\/science.149.3685.754","volume":"149","author":"RW Atchison","year":"1965","unstructured":"Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. 1965;149(3685):754\u20136.","journal-title":"Science"},{"key":"756_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","volume":"14","author":"A Kruzik","year":"2019","unstructured":"Kruzik A, Fetahagic D, Hartlieb B, Dorn S, Koppensteiner H, Horling FM, et al. Prevalence of anti-adeno-associated virus immune responses in international cohorts of Hhalthy donors. Mol Ther. 2019;14:126\u201333. https:\/\/doi.org\/10.1016\/j.omtm.2019.05.014.","journal-title":"Mol Ther"},{"issue":"3","key":"756_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo R, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199(3):381\u201390.","journal-title":"J Infect Dis"},{"issue":"6","key":"756_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin S, Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704\u201312. https:\/\/doi.org\/10.1089\/hum.2009.182.","journal-title":"Hum Gene Ther"},{"key":"756_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02137-16","author":"D Huser","year":"2017","unstructured":"Huser D, High prevalence of infectious adeno-associated virus (AAV) in human peripheral blood mononuclear cells indicative of T lymphocytes as sites of AAV persistence. J Virol. 2017. https:\/\/doi.org\/10.1128\/JVI.02137-16.","journal-title":"J Virol"},{"issue":"1","key":"756_CR37","doi-asserted-by":"publisher","first-page":"15941","DOI":"10.1038\/s41598-024-66546-4","volume":"14","author":"M Navarro-Oliveros","year":"2024","unstructured":"Navarro-Oliveros M, Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors. Sci Rep. 2024;14(1):15941.","journal-title":"Sci Rep"},{"issue":"11","key":"756_CR38","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1038\/mt.2011.81","volume":"19","author":"H Li","year":"2011","unstructured":"Li H, Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol Ther. 2011;19(11):2021\u201330. https:\/\/doi.org\/10.1038\/mt.2011.81.","journal-title":"Mol Ther"},{"issue":"11","key":"756_CR39","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1089\/hum.2017.150","volume":"28","author":"C Vandamme","year":"2017","unstructured":"Vandamme C, Adjali O, Mingozzi F. Unraveling the complex story of immune responses to AAV vectors trial after trial. Hum Gene Ther. 2017;28(11):1061\u201374. https:\/\/doi.org\/10.1089\/hum.2017.150.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"756_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342\u20137.","journal-title":"Nat Med"},{"issue":"25","key":"756_CR41","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC,  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1108046.","journal-title":"N Engl J Med"},{"issue":"2","key":"756_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nbt1182","volume":"24","author":"N Maheshri","year":"2006","unstructured":"Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol. 2006;24(2):198\u2013204. https:\/\/doi.org\/10.1038\/nbt1182.","journal-title":"Nat Biotechnol"},{"issue":"24","key":"756_CR43","doi-asserted-by":"publisher","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","volume":"114","author":"LV Tse","year":"2017","unstructured":"Tse LV, Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci USA. 2017;114(24):E4812\u201321. https:\/\/doi.org\/10.1073\/pnas.1704766114.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"756_CR44","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","volume":"124","author":"J Guy","year":"2017","unstructured":"Guy J, Feuer WJ, Davis JL, Porciatti V, Gonzalez PJ, Koilkonda RD, et al. Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results. Ophthalmology. 2017;124(11):1621\u201334. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.016.","journal-title":"Ophthalmology"},{"key":"756_CR45","unstructured":"Luxturna (voretigene neparvovec-rzyl) [package insert]. Spark Therapeutics, Inc.; 2017. https:\/\/www.fda.gov\/media\/109906\/download. Accessed 10 Jul 2023."},{"issue":"20","key":"756_CR46","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"CW Christine","year":"2009","unstructured":"Christine CW, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009;73(20):1662\u20139.","journal-title":"Neurology"},{"key":"756_CR47","unstructured":"Kebilidi (eladocagene exuparvovec-tneq) [package insert]. PTC Therapeutics, Inc.; 2024. https:\/\/www.fda.gov\/media\/183530\/download. Accessed 13 Dec 2024."},{"issue":"194","key":"756_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005795","volume":"5","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med. 2013;5(194):194ra92.","journal-title":"Sci Transl Med"},{"issue":"7","key":"756_CR49","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","volume":"26","author":"C Leborgne","year":"2020","unstructured":"Leborgne C, IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020;26(7):1096\u2013101.","journal-title":"Nat Med"},{"issue":"5","key":"756_CR50","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/jca.22069","volume":"38","author":"S Boedecker-Lips","year":"2023","unstructured":"Boedecker-Lips S, Efficient removal of antibodies to adeno-associated viruses by immunoadsorption. J Clin Apher. 2023;38(5):590\u2013601. https:\/\/doi.org\/10.1002\/jca.22069.","journal-title":"J Clin Apher"},{"issue":"17","key":"756_CR51","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/bloodadvances.2019000380","volume":"3","author":"D Salas","year":"2019","unstructured":"Salas D, Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates. Blood Adv. 2019;3(17):2632\u201341.","journal-title":"Blood Adv"},{"issue":"1","key":"756_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jmv.21360","volume":"81","author":"SL Murphy","year":"2009","unstructured":"Murphy SL, Li H, Mingozzi F, Sabatino DE, Hui DJ, Edmonson SA, et al. Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J Med Virol. 2009;81(1):65\u201374. https:\/\/doi.org\/10.1002\/jmv.21360.","journal-title":"J Med Virol"},{"key":"756_CR53","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.addr.2021.01.017","volume":"170","author":"EA Chowdhury","year":"2021","unstructured":"Chowdhury EA,  Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic\/pharmacodynamic (PK\/PD) models. Adv Drug Deliv Rev. 2021;170:214\u201337. https:\/\/doi.org\/10.1016\/j.addr.2021.01.017.","journal-title":"Adv Drug Deliv Rev"},{"key":"756_CR54","unstructured":"Roctavian (valoctocogene roxaparvovec-rvox) [package insert]. BioMarin Pharmaceutical Inc.; 2023. https:\/\/www.fda.gov\/media\/169937\/download. Accessed 10 Jul 2023."},{"issue":"8","key":"756_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3505","volume":"25","author":"N Baatartsogt","year":"2023","unstructured":"Baatartsogt N, Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice. J Gene Med. 2023;25(8):e3505. https:\/\/doi.org\/10.1002\/jgm.3505.","journal-title":"J Gene Med"},{"issue":"17","key":"756_CR56","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/sj.gt.3302766","volume":"13","author":"C Riviere","year":"2006","unstructured":"Riviere C, Danos O, Douar AM. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther. 2006;13(17):1300\u20138. https:\/\/doi.org\/10.1038\/sj.gt.3302766.","journal-title":"Gene Ther"},{"issue":"8","key":"756_CR57","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","volume":"25","author":"A Majowicz","year":"2017","unstructured":"Majowicz A, Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5(ch) and AAV1. Mol Ther. 2017;25(8):1831\u201342. https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.003.","journal-title":"Mol Ther"},{"key":"756_CR58","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.omtm.2020.05.001","volume":"17","author":"BJ Samelson-Jones","year":"2020","unstructured":"Samelson-Jones BJ, Timing of intensive immunosuppression impacts risk of transgene antibodies after AAV gene therapy in nonhuman primates. Mol Ther. 2020;17:1129\u201338. https:\/\/doi.org\/10.1016\/j.omtm.2020.05.001.","journal-title":"Mol Ther"},{"key":"756_CR59","unstructured":"Beqveztm (fidanacogene elaparvovec-dzkt) [package insert]. Pfizer, Inc.; 2024. https:\/\/www.fda.gov\/media\/178140\/download. Accessed 3 Jun 2024."},{"issue":"5","key":"756_CR60","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/hae.14100","volume":"26","author":"CJ Jonker","year":"2020","unstructured":"Jonker CJ,  Inhibitor development in previously untreated patients with severe haemophilia: a comparison of included patients and outcomes between a clinical study and a registry-based study. Haemophilia. 2020;26(5):809\u201316. https:\/\/doi.org\/10.1111\/hae.14100.","journal-title":"Haemophilia"},{"issue":"1","key":"756_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0222-9","volume":"5","author":"KM Hege","year":"2017","unstructured":"Hege KM, Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5(1):22. https:\/\/doi.org\/10.1186\/s40425-017-0222-9.","journal-title":"J Immunother Cancer"},{"key":"756_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114421","volume":"188","author":"T Qi","year":"2022","unstructured":"Qi T, McGrath K, Ranganathan R, Dotti G, Cao Y. Cellular kinetics: a clinical and computational review of CAR-T cell pharmacology. Adv Drug Deliv Rev. 2022;188:114421. https:\/\/doi.org\/10.1016\/j.addr.2022.114421.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"756_CR63","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385. https:\/\/doi.org\/10.1038\/s41571-019-0184-6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"756_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","volume":"117","author":"CH Lamers","year":"2011","unstructured":"Lamers CH,  Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood. 2011;117(1):72\u201382.","journal-title":"Blood"},{"key":"756_CR65","unstructured":"Yescarta (axicabtagene ciloleucel) [package insert]. Kite Pharma; 2017. https:\/\/www.fda.gov\/media\/108377\/download. Accessed 16 Dec 2024."},{"key":"756_CR66","unstructured":"Kymriah (tisagenlecleucel). Novartis Pharmaceutical Corperation; 2017. https:\/\/www.fda.gov\/media\/107296\/download. Accessed 16 Dec 2024."},{"issue":"6","key":"756_CR67","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL,  Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18(6):379\u201393.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10266","key":"756_CR68","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin R,  Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396(10266):1885\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(20)32334-5.","journal-title":"Lancet"},{"key":"756_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005701","author":"F Song","year":"2023","unstructured":"Song F, Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-005701.","journal-title":"J Immunother Cancer"},{"key":"756_CR70","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.omtm.2022.02.002","volume":"24","author":"C Huichalaf","year":"2022","unstructured":"Huichalaf C, Perfitt TL, Kuperman A, Gooch R, Kovi RC, Brenneman KA, et al. In\u00a0vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency. Mol Ther. 2022;24:367\u201378. https:\/\/doi.org\/10.1016\/j.omtm.2022.02.002.","journal-title":"Mol Ther"},{"issue":"9","key":"756_CR71","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/mt.2012.119","volume":"20","author":"DA Suhy","year":"2012","unstructured":"Suhy DA,  Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther. 2012;20(9):1737\u201349. https:\/\/doi.org\/10.1038\/mt.2012.119.","journal-title":"Mol Ther"},{"key":"756_CR72","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.omtm.2022.01.013","volume":"24","author":"N Buss","year":"2022","unstructured":"Buss N,  Characterization of AAV-mediated dorsal root ganglionopathy. Mol Ther. 2022;24:342\u201354. https:\/\/doi.org\/10.1016\/j.omtm.2022.01.013.","journal-title":"Mol Ther"},{"key":"756_CR73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-9139-6_8","volume":"1950","author":"DJ Gessler","year":"2019","unstructured":"Gessler DJ,  Intravenous infusion of AAV for widespread gene delivery to the Nervous system. Methods Mol Biol. 2019;1950:143\u201363.","journal-title":"Methods Mol Biol"},{"key":"756_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115363","volume":"211","author":"D Ye","year":"2024","unstructured":"Ye D,  Adeno-associated virus vector delivery to the brain: technology advancements and clinical applications. Adv Drug Deliv Rev. 2024;211:115363. https:\/\/doi.org\/10.1016\/j.addr.2024.115363.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"756_CR75","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ymthe.2024.01.024","volume":"32","author":"M Drouyer","year":"2024","unstructured":"Drouyer M,  Development of CNS tropic AAV1-like variants with reduced liver-targeting following systemic administration in mice. Mol Ther. 2024;32(3):818\u201336. https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.024.","journal-title":"Mol Ther"},{"issue":"23-24","key":"756_CR76","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1089\/hum.2022.138","volume":"33","author":"S Prasad","year":"2022","unstructured":"Prasad S,  Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches. Hum Gene Ther. 2022;33(23\u201324):1228\u201345. https:\/\/doi.org\/10.1089\/hum.2022.138.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"756_CR77","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","volume":"131","author":"K Pieper","year":"2013","unstructured":"Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol. 2013;131(4):959\u201371. https:\/\/doi.org\/10.1016\/j.jaci.2013.01.046.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"756_CR78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nri3567","volume":"14","author":"DL Farber","year":"2014","unstructured":"Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(1):24\u201335.","journal-title":"Nat Rev Immunol"},{"key":"756_CR79","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","volume":"26","author":"TY Yang","year":"2022","unstructured":"Yang TY,  Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper. Mol Ther. 2022;26:471\u201394. https:\/\/doi.org\/10.1016\/j.omtm.2022.07.018.","journal-title":"Mol Ther"},{"issue":"4","key":"756_CR80","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/hum.2016.172","volume":"28","author":"HCJ Ertl","year":"2017","unstructured":"Ertl HCJ, High KA. impact of AAV capsid-specific T-cell responses on design and outcome of clinical gene transfer trials with recombinant adeno-associated viral vectors: an evolving controversy. Hum Gene Ther. 2017;28(4):328\u201337.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"756_CR81","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00262-025-04001-7","volume":"74","author":"G Wang","year":"2025","unstructured":"Wang G,  Be cautious to adopt a second CAR T-cell infusion after failure of CD19\/CD22 cocktail CAR T-cell therapy in relapsed\/refractory B-NHL. Cancer Immunol Immunother. 2025;74(5):156.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"756_CR82","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R,  Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"756_CR83","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","volume":"108","author":"R Dingman","year":"2019","unstructured":"Dingman R, Balu-Iyer SV. Immunogenicity of protein pharmaceuticals. J Pharm Sci. 2019;108(5):1637\u201354.","journal-title":"J Pharm Sci"},{"issue":"Suppl. 4","key":"756_CR84","doi-asserted-by":"publisher","first-page":"iv9","DOI":"10.1093\/ndt\/gfh1087","volume":"20","author":"IC Macdougall","year":"2005","unstructured":"Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant. 2005;20(Suppl. 4):iv9-15.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"756_CR85","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41467-021-21935-5","volume":"12","author":"TP Worner","year":"2021","unstructured":"Worner TP,  Adeno-associated virus capsid assembly is divergent and stochastic. Nat Commun. 2021;12(1):1642.","journal-title":"Nat Commun"},{"issue":"1","key":"756_CR86","doi-asserted-by":"publisher","first-page":"2333729","DOI":"10.1080\/19420862.2024.2333729","volume":"16","author":"AE Mattei","year":"2024","unstructured":"Mattei AE,  In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies. MAbs. 2024;16(1):2333729.","journal-title":"MAbs"},{"issue":"4","key":"756_CR87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1208\/s12248-023-00820-7","volume":"25","author":"J Gokemeijer","year":"2023","unstructured":"Gokemeijer J,  Survey outcome on immunogenicity risk assessment tools for biotherapeutics: an insight into consensus on methods, application, and utility in drug development. AAPS J. 2023;25(4):55.","journal-title":"AAPS J"},{"key":"756_CR88","doi-asserted-by":"publisher","first-page":"1212136","DOI":"10.3389\/fimmu.2023.1212136","volume":"14","author":"CA Brito-Sierra","year":"2023","unstructured":"Brito-Sierra CA,  The HLA class I immunopeptidomes of AAV capsid proteins. Front Immunol. 2023;14:1212136.","journal-title":"Front Immunol"},{"key":"756_CR89","doi-asserted-by":"publisher","first-page":"1271120","DOI":"10.3389\/fimmu.2023.1271120","volume":"14","author":"W Jankowski","year":"2023","unstructured":"Jankowski W,  The MHC associated peptide proteomics assay is a useful tool for the non-clinical assessment of immunogenicity. Front Immunol. 2023;14:1271120.","journal-title":"Front Immunol"},{"issue":"12","key":"756_CR90","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1016\/j.xphs.2024.09.006","volume":"113","author":"N Jarvi","year":"2024","unstructured":"Jarvi N, Hofman K, Venkatesh A, Gorecki E, Balu-Iyer SV. Immunogenicity risk assessment of empty capsids present in adeno-associated viral vectors using predictive innate immune responses. J Pharm Sci. 2024;113(12):3457\u201369. https:\/\/doi.org\/10.1016\/j.xphs.2024.09.006.","journal-title":"J Pharm Sci"},{"issue":"11","key":"756_CR91","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1002\/jps.24592","volume":"104","author":"AM Fathallah","year":"2015","unstructured":"Fathallah AM,  The effect of small oligomeric protein aggregates on the immunogenicity of intravenous and subcutaneous administered aantibodies. J Pharm Sci. 2015;104(11):3691\u2013702. https:\/\/doi.org\/10.1002\/jps.24592.","journal-title":"J Pharm Sci"},{"issue":"4","key":"756_CR92","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2567.2008.02922.x","volume":"126","author":"RJ Dearman","year":"2009","unstructured":"Dearman RJ,  Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. Immunology. 2009;126(4):475\u201384.","journal-title":"Immunology"},{"key":"756_CR93","unstructured":"MacKay VL,  US Patent 5,648,219. 1997."},{"key":"756_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674242","volume":"12","author":"M Muhuri","year":"2021","unstructured":"Muhuri M,  Novel combinatorial microRNA-binding sites in AAV vectors synergistically diminish antigen presentation and transgene immunity for efficient and stable transduction. Front Immunol. 2021;12:674242.","journal-title":"Front Immunol"},{"issue":"2","key":"756_CR95","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1182\/blood.V100.2.701","volume":"100","author":"AJ Masterson","year":"2002","unstructured":"Masterson AJ,  MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood. 2002;100(2):701\u20133.","journal-title":"Blood"},{"issue":"2","key":"756_CR96","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1365-2567.2005.02274.x","volume":"117","author":"K Larsson","year":"2006","unstructured":"Larsson K, Lindstedt M, Borrebaeck CA. Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells. Immunology. 2006;117(2):156\u201366.","journal-title":"Immunology"},{"issue":"1","key":"756_CR97","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/emm.2006.9","volume":"38","author":"KD Kim","year":"2006","unstructured":"Kim KD,  Impaired responses of leukemic dendritic cells derived from a human myeloid cell line to LPS stimulation. Exp Mol Med. 2006;38(1):72\u201384.","journal-title":"Exp Mol Med"},{"key":"756_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1298721","volume":"15","author":"L Lu","year":"2024","unstructured":"Lu L,  Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccines in vitro. Front Immunol. 2024;15:1298721.","journal-title":"Front Immunol"},{"key":"756_CR99","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-4615-2930-9_46","volume":"329","author":"JH Peters","year":"1993","unstructured":"Peters JH,  Signals required for differentiating dendritic cells from human monocytes in vitro. Adv Exp Med Biol. 1993;329:275\u201380.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"756_CR100","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11095-024-03678-2","volume":"41","author":"JR Cohen","year":"2024","unstructured":"Cohen JR,  A high threshold of biotherapeutic aggregate numbers is needed to induce an immunogenic response in vitro, in vivo, and in the clinic. Pharm Res. 2024;41(4):651\u201372.","journal-title":"Pharm Res"},{"issue":"1","key":"756_CR101","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s43856-023-00413-7","volume":"3","author":"NL Jarvi","year":"2023","unstructured":"Jarvi NL, Balu-Iyer SV. A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics. Commun Med. 2023;3(1):174.","journal-title":"Commun Med"},{"issue":"3","key":"756_CR102","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding FA,  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2(3):256\u201365.","journal-title":"MAbs"},{"key":"756_CR103","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-0716-2376-3_9","volume":"2508","author":"MB Lemieszek","year":"2022","unstructured":"Lemieszek MB, Findlay SD, Siegers GM. CellTrace violet flow cytometric assay to assess cell proliferation. Methods Mol Biol. 2022;2508:101\u201314.","journal-title":"Methods Mol Biol"},{"key":"756_CR104","first-page":"2559","volume":"44","author":"BJ Quah","year":"2010","unstructured":"Quah BJ, Parish CR. The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation. J Vis Exp. 2010;44:2559.","journal-title":"J Vis Exp"},{"key":"756_CR105","doi-asserted-by":"publisher","first-page":"1450524","DOI":"10.3389\/fimmu.2024.1450524","volume":"15","author":"SJ Holtkamp","year":"2024","unstructured":"Holtkamp SJ,  Polyfunctional T cells and unique cytokine clusters imprint the anti rAAV2\/rAAV9 vector immune response. Front Immunol. 2024;15:1450524.","journal-title":"Front Immunol"},{"issue":"11","key":"756_CR106","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1099\/vir.0.014175-0","volume":"90","author":"D Madsen","year":"2009","unstructured":"Madsen D,  Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1. J Gen Virol. 2009;90(11):2622\u201333.","journal-title":"J Gen Virol"},{"key":"756_CR107","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.omtm.2021.05.012","volume":"22","author":"KS Patton","year":"2021","unstructured":"Patton KS,  Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-gamma ELISpot method. Mol Ther Methods Clin Dev. 2021;22:183\u201395.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"756_CR108","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","volume":"114","author":"F Mingozzi","year":"2009","unstructured":"Mingozzi F,  AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood. 2009;114(10):2077\u201386.","journal-title":"Blood"},{"issue":"3","key":"756_CR109","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1208\/s12248-023-00814-5","volume":"25","author":"B Gorovits","year":"2023","unstructured":"Gorovits B,  Evaluation of cellular immune response to adeno-associated virus-based gene therapy. AAPS J. 2023;25(3):47.","journal-title":"AAPS J"},{"issue":"2","key":"756_CR110","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.xphs.2024.11.009","volume":"114","author":"Y Dai","year":"2025","unstructured":"Dai Y,  Monitoring antigen-specific cellular immune response using an RT-ddPCR-based assay for IFN-gamma gene expression. J Pharm Sci. 2025;114(2):1017\u201323.","journal-title":"J Pharm Sci"},{"key":"756_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2022.116897","volume":"158","author":"Y Hou","year":"2023","unstructured":"Hou Y, Chen S, Zheng Y, Zheng X, Lin J-M. Droplet-based digital PCR (ddPCR) and its applications. Trends Anal Chem. 2023;158:116897. https:\/\/doi.org\/10.1016\/j.trac.2022.116897.","journal-title":"Trends Anal Chem"},{"key":"756_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052673","author":"E Galli","year":"2024","unstructured":"Galli E,  Unlocking predictive power: quantitative assessment of CAR-T expansion with digital droplet polymerase chain reaction (ddPCR). Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25052673.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"756_CR113","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","volume":"22","author":"TK Kishimoto","year":"2022","unstructured":"Kishimoto TK, Samulski RJ. Addressing high dose AAV toxicity: \u201cone and done\u201d or \u201cslower and lower\u201d? Expert Opin Biol Ther. 2022;22(9):1067\u201371. https:\/\/doi.org\/10.1080\/14712598.2022.2060737.","journal-title":"Expert Opin Biol Ther"},{"key":"756_CR114","first-page":"1923","volume":"37","author":"M Costabile","year":"2010","unstructured":"Costabile M. Measuring the 50% haemolytic complement (CH50) activity of serum. J Vis Exp. 2010;37:1923.","journal-title":"J Vis Exp"},{"key":"756_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999021","volume":"13","author":"CJ Smith","year":"2022","unstructured":"Smith CJ, Ross N, Kamal A, Kim KY, Kropf E, Deschatelets P, et al. Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood. Front Immunol. 2022;13:999021.","journal-title":"Front Immunol"},{"issue":"6","key":"756_CR116","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1128\/JVI.01990-07","volume":"82","author":"AK Zaiss","year":"2008","unstructured":"Zaiss AK, Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol. 2008;82(6):2727\u201340.","journal-title":"J Virol"},{"issue":"24","key":"756_CR117","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","volume":"117","author":"AT Martino","year":"2011","unstructured":"Martino AT, The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood. 2011;117(24):6459\u201368.","journal-title":"Blood"},{"issue":"40","key":"756_CR118","doi-asserted-by":"publisher","first-page":"17158","DOI":"10.1073\/pnas.0909520106","volume":"106","author":"Y Lu","year":"2009","unstructured":"Lu Y, Song S. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci USA. 2009;106(40):17158\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"756_CR119","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/gt.2014.103","volume":"22","author":"R Thwaite","year":"2015","unstructured":"Thwaite R, AAVrh.10 immunogenicity in mice and humans: relevance of antibody cross-reactivity in human gene therapy. Gene Ther. 2015;22(2):196\u2013201.","journal-title":"Gene Ther"},{"issue":"21","key":"756_CR120","doi-asserted-by":"publisher","first-page":"11840","DOI":"10.1128\/JVI.01253-07","volume":"81","author":"J Lin","year":"2007","unstructured":"Lin J, Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. J Virol. 2007;81(21):11840\u20139.","journal-title":"J Virol"},{"issue":"12","key":"756_CR121","first-page":"3958","volume":"117","author":"SW Lin","year":"2007","unstructured":"Lin SW, Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Investig. 2007;117(12):3958\u201370.","journal-title":"J Clin Investig"},{"issue":"3","key":"756_CR122","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/hum.2007.001","volume":"18","author":"L Wang","year":"2007","unstructured":"Wang L, Figueredo J, Calcedo R, Lin J, Wilson JM. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther. 2007;18(3):185\u201394. https:\/\/doi.org\/10.1089\/hum.2007.001.","journal-title":"Hum Gene Ther"},{"key":"756_CR123","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omtm.2022.08.008","volume":"27","author":"BB Duncan","year":"2022","unstructured":"Duncan BB, Dunbar CE, Ishii K. Applying a clinical lens to animal models of CAR-T cell therapies. Mol Ther. 2022;27:17\u201331. https:\/\/doi.org\/10.1016\/j.omtm.2022.08.008.","journal-title":"Mol Ther"},{"issue":"12","key":"756_CR124","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/sj.leu.2401236","volume":"12","author":"WA Hudson","year":"1998","unstructured":"Hudson WA, Li Q, Le C, Kersey JH. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia. 1998;12(12):2029\u201333. https:\/\/doi.org\/10.1038\/sj.leu.2401236.","journal-title":"Leukemia"},{"issue":"15","key":"756_CR125","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1158\/0008-5472.CAN-15-0727","volume":"75","author":"JW Cassidy","year":"2015","unstructured":"Cassidy JW, Caldas C, Bruna A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 2015;75(15):2963\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0727.","journal-title":"Cancer Res"},{"issue":"5","key":"756_CR126","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/01926233231202995","volume":"51","author":"S Chandra","year":"2023","unstructured":"Chandra S, Long BR, Fonck C, Melton AC, Arens J, Woloszynek J, Safety findings of dosing gene therapy vectors in NHP with pre-existing or treatment-emergent anti-capsid antibodies. Toxicol Pathol. 2023;51(5):246\u201356. https:\/\/doi.org\/10.1177\/01926233231202995.","journal-title":"Toxicol Pathol"},{"issue":"7","key":"756_CR127","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","volume":"110","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE, Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood. 2007;110(7):2334\u201341. https:\/\/doi.org\/10.1182\/blood-2007-03-080093.","journal-title":"Blood"},{"key":"756_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.762209","volume":"9","author":"ML Arotcarena","year":"2021","unstructured":"Arotcarena ML, Pilot study assessing the impact of intrathecal administration of variants AAV-PHP.B and AAV-PHP.eB on brain transduction in adult rhesus macaques. Front Bioeng Biotechnol. 2021;9:762209.","journal-title":"Front Bioeng Biotechnol"},{"key":"756_CR129","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","volume":"17","author":"K Bey","year":"2020","unstructured":"Bey K, Deniaud J, Dubreil L, Joussemet B, Cristini J, Ciron C, et al. Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases? Mol Ther. 2020;17:771\u201384. https:\/\/doi.org\/10.1016\/j.omtm.2020.04.001.","journal-title":"Mol Ther"},{"key":"756_CR130","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.omtm.2022.01.011","volume":"24","author":"D Ail","year":"2022","unstructured":"Ail D, Ren D, Brazhnikova E, Nouvel-Jaillard C, Bertin S, Mirashrafi SB, et al. Systemic and local immune responses to intraocular AAV vector administration in non-human primates. Mol Ther. 2022;24:306\u201316. https:\/\/doi.org\/10.1016\/j.omtm.2022.01.011.","journal-title":"Mol Ther"},{"issue":"1","key":"756_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101195","volume":"32","author":"RA Potter","year":"2024","unstructured":"Potter RA, Peterson EL, Griffin D, Cooper Olson G, Lewis S, Cochran K, et al. Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74. Mol Ther. 2024;32(1):101195. https:\/\/doi.org\/10.1016\/j.omtm.2024.101195.","journal-title":"Mol Ther"},{"key":"756_CR132","doi-asserted-by":"publisher","first-page":"1094279","DOI":"10.3389\/fimmu.2023.1094279","volume":"14","author":"J Hordeaux","year":"2023","unstructured":"Hordeaux J, Immune transgene-dependent myocarditis in macaques after systemic administration of adeno-associated virus expressing human acid alpha-glucosidase. Front Immunol. 2023;14:1094279.","journal-title":"Front Immunol"},{"issue":"4","key":"756_CR133","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","volume":"32","author":"J Hordeaux","year":"2024","unstructured":"Hordeaux J, Lamontagne RJ, Song C, Buchlis G, Dyer C, Buza EL, et al. High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury. Mol Ther. 2024;32(4):952\u201368. https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.002.","journal-title":"Mol Ther"},{"issue":"3","key":"756_CR134","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29(3):285\u201398. https:\/\/doi.org\/10.1089\/hum.2018.015.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"756_CR135","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","volume":"3","author":"C Berger","year":"2015","unstructured":"Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res. 2015;3(2):206\u201316. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0163.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"756_CR136","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","volume":"8","author":"A Taraseviciute","year":"2018","unstructured":"Taraseviciute A, Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 2018;8(6):750\u201363.","journal-title":"Cancer Discov"},{"key":"756_CR137","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","volume":"12","author":"H B\u00fcning","year":"2019","unstructured":"B\u00fcning H, Srivastava A. Capsid odifications for targeting and improving the efficacy of AAV vectors. Mol Ther Methods Clin Dev. 2019;12:248\u201365.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"756_CR138","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01011-18","author":"AR Giles","year":"2018","unstructured":"Giles AR, Mapping an adeno-associated virus 9-specific neutralizing epitope to develop next-generation gene delivery vectors. J Virol. 2018. https:\/\/doi.org\/10.1128\/JVI.01011-18.","journal-title":"J Virol"},{"issue":"9","key":"756_CR139","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.amjmed.2023.03.033","volume":"136","author":"EY Adashi","year":"2023","unstructured":"Adashi EY, O\u2019Mahony DP, Cohen IG. The FDA modernization act 2.0: drug testing in animals is rendered optional. Am J Med. 2023;136(9):853\u20134.","journal-title":"Am J Med"},{"key":"756_CR140","doi-asserted-by":"publisher","first-page":"1011143","DOI":"10.3389\/fimmu.2022.1011143","volume":"13","author":"RM Ramamurthy","year":"2022","unstructured":"Ramamurthy RM, Organoids and microphysiological systems: promising models for accelerating AAV gene therapy studies. Front Immunol. 2022;13:1011143.","journal-title":"Front Immunol"},{"issue":"14","key":"756_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103241","volume":"9","author":"G Goyal","year":"2022","unstructured":"Goyal G, Prabhala P, Mahajan G, Bausk B, Gilboa T, Xie L, et al. Ectopic lymphoid follicle formation and human seasonal influenza vaccination responses recapitulated in an organ-on-a-chip. Adv Sci. 2022;9(14):e2103241. https:\/\/doi.org\/10.1002\/advs.202103241.","journal-title":"Adv Sci"},{"issue":"2","key":"756_CR142","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30(2):338\u201341.","journal-title":"Nat Med"},{"issue":"4","key":"756_CR143","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","volume":"5","author":"M Abou-El-Enein","year":"2024","unstructured":"Abou-El-Enein M. The fate(s) of CAR T-cell therapy: navigating the risks of CAR+ T-cell malignancy. Blood Cancer Discov. 2024;5(4):249\u201357.","journal-title":"Blood Cancer Discov"},{"key":"756_CR144","unstructured":"Elevidys (delandistrogene moxeparvovec-rokl) [package insert]. Sarepta Therapeutics, Inc.; 2024. https:\/\/www.fda.gov\/media\/169679\/download. Accessed 16 Jul 2024."},{"key":"756_CR145","unstructured":"Hemgenix (etranacogene dezaparvovec-drlb) [package insert]. CSL Behring; 2022. https:\/\/www.fda.gov\/media\/163467\/download. Accessed 16 Jul 2024."},{"key":"756_CR146","unstructured":"Zolgensma\u00ae (onasemnogene abeparvovec-xioi) [package insert]. Novartis Gene Therapies; 2023. https:\/\/www.fda.gov\/media\/126109\/download. Accessed 16 Jul 2024."},{"key":"756_CR147","unstructured":"Abecma (idecabtagene vicleucel) [package insert]. Bristol-Myers Squibb; 2024. https:\/\/www.fda.gov\/media\/147055\/download?attachment. Accessed 20 Jan 2025."},{"key":"756_CR148","unstructured":"Aucatzyl (obecabtagene autoleuce) [package insert]. Autolus Inc.; 2024. https:\/\/www.fda.gov\/media\/183463\/download?attachment. Accessed 20 Jan 2025."},{"key":"756_CR149","unstructured":"Breyanzi (lisocabtagene maraleucel) [package insert]. Bristol-Myers Squibb; 2024. https:\/\/www.fda.gov\/media\/145711\/download?attachment. Accessed 20 Jan 2025."},{"key":"756_CR150","unstructured":"Carvykti (ciltacabtagene autoleucel) [package insert]. Janssen Biotech, Inc.; 2024. https:\/\/www.fda.gov\/media\/156560\/download?attachment. Accessed 20 Jan 2025."},{"key":"756_CR151","unstructured":"Tecartus (brexucabtagene autoleucel) [package insert]. Kite Pharmaceuticals, Inc.; 2024. https:\/\/www.fda.gov\/media\/140409\/download?attachment. Accessed 20 Jan 2025."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00756-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00756-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00756-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:02:28Z","timestamp":1774422148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00756-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":151,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00756-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"2 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kirk Hofman, Priyanka Jangied, and Sathy V. Balu-Iyer have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Each author contributed equally to this work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}